ES2703814T3 - Terapia génica para la enfermedad de Fabry - Google Patents
Terapia génica para la enfermedad de Fabry Download PDFInfo
- Publication number
- ES2703814T3 ES2703814T3 ES16721916T ES16721916T ES2703814T3 ES 2703814 T3 ES2703814 T3 ES 2703814T3 ES 16721916 T ES16721916 T ES 16721916T ES 16721916 T ES16721916 T ES 16721916T ES 2703814 T3 ES2703814 T3 ES 2703814T3
- Authority
- ES
- Spain
- Prior art keywords
- vector
- galactosidase
- nucleic acid
- sequence
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024720 Fabry Disease Diseases 0.000 title claims description 31
- 238000001415 gene therapy Methods 0.000 title description 14
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 77
- 239000002773 nucleotide Substances 0.000 claims abstract description 75
- 108010030291 alpha-Galactosidase Proteins 0.000 claims abstract description 60
- 102000005840 alpha-Galactosidase Human genes 0.000 claims abstract description 60
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 48
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 108020004705 Codon Proteins 0.000 claims abstract description 25
- 210000004185 liver Anatomy 0.000 claims abstract description 22
- 239000013598 vector Substances 0.000 claims description 103
- 238000000034 method Methods 0.000 claims description 30
- 239000013607 AAV vector Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000005457 optimization Methods 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 description 43
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 28
- 241000125945 Protoparvovirus Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 15
- 210000000234 capsid Anatomy 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000012546 transfer Methods 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 8
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 7
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 7
- 241000702421 Dependoparvovirus Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 6
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000002339 glycosphingolipids Chemical class 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 4
- 241000701945 Parvoviridae Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000000635 electron micrograph Methods 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- YUDPTGPSBJVHCN-CHUNWDLHSA-N 4-methylumbelliferyl alpha-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-CHUNWDLHSA-N 0.000 description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241000121250 Parvovirinae Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013609 scAAV vector Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 241000425548 Adeno-associated virus 3A Species 0.000 description 1
- 241000958487 Adeno-associated virus 3B Species 0.000 description 1
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000121256 Densovirinae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100028993 Hippocalcin-like protein 1 Human genes 0.000 description 1
- 101000870662 Homo sapiens ATP-dependent RNA helicase DDX3X Proteins 0.000 description 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 1
- 101000838883 Homo sapiens Hippocalcin-like protein 1 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010049936 agalsidase alfa Proteins 0.000 description 1
- 229960001239 agalsidase alfa Drugs 0.000 description 1
- 108010056760 agalsidase beta Proteins 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- -1 alpha-galactosyl moieties Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 238000001239 high-resolution electron microscopy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002812 neutral glycosphingolipids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1508025.2A GB201508025D0 (en) | 2015-05-11 | 2015-05-11 | Fabry disease gene therapy |
| PCT/GB2016/051328 WO2016181122A1 (en) | 2015-05-11 | 2016-05-10 | Fabry disease gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2703814T3 true ES2703814T3 (es) | 2019-03-12 |
Family
ID=53489437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16721916T Active ES2703814T3 (es) | 2015-05-11 | 2016-05-10 | Terapia génica para la enfermedad de Fabry |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11103596B2 (enExample) |
| EP (2) | EP3470088A1 (enExample) |
| JP (1) | JP6688812B2 (enExample) |
| KR (1) | KR20180012772A (enExample) |
| CN (1) | CN107980063B (enExample) |
| AU (1) | AU2016261453C1 (enExample) |
| CA (1) | CA2985935C (enExample) |
| DK (1) | DK3244931T3 (enExample) |
| ES (1) | ES2703814T3 (enExample) |
| GB (1) | GB201508025D0 (enExample) |
| HR (1) | HRP20190165T1 (enExample) |
| LT (1) | LT3244931T (enExample) |
| PL (1) | PL3244931T3 (enExample) |
| PT (1) | PT3244931T (enExample) |
| TR (1) | TR201820102T4 (enExample) |
| TW (1) | TW201706412A (enExample) |
| WO (1) | WO2016181122A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| CA2996420A1 (en) | 2015-09-28 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for antibody-evading virus vectors |
| EP3458590B9 (en) | 2016-05-18 | 2021-08-18 | ModernaTX, Inc. | Polynucleotides encoding -galactosidase a for the treatment of fabry disease |
| SG11202009451VA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| WO2019210187A1 (en) * | 2018-04-26 | 2019-10-31 | The University Of North Carolina At Chapel Hill | Methods and compositions for treatment of hemophilia |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| MX2021001901A (es) * | 2018-08-20 | 2021-05-27 | Ucl Business Ltd | Nucleotidos de codificacion del factor ix. |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| WO2020077114A2 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
| SG11202110146VA (en) | 2019-03-21 | 2021-10-28 | Stridebio Inc | Recombinant adeno-associated virus vectors |
| CN114423428A (zh) * | 2019-08-07 | 2022-04-29 | 阿米库斯治疗学公司 | 治疗在gla基因中具有突变的患者的法布里病的方法 |
| EP4045525A1 (en) | 2019-10-17 | 2022-08-24 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| US20220387558A1 (en) | 2019-11-01 | 2022-12-08 | Freeline Therapeutics Limited | Transcription regulatory elements |
| WO2021183895A1 (en) * | 2020-03-13 | 2021-09-16 | Biomarin Pharmaceutical Inc. | Treatment of fabry disease with aav gene therapy vectors |
| TWI769795B (zh) * | 2020-04-27 | 2022-07-01 | 美商４Ｄ分子療法公司 | 密碼子優化的ｇｌａ基因及其用途 |
| IL297756A (en) * | 2020-04-29 | 2022-12-01 | Saliogen Therapeutics Inc | Compositions and methods for treatment of familial hypercholesterolemia and elevated low-density lipoprotein cholesterol |
| TW202227632A (zh) | 2020-08-19 | 2022-07-16 | 美商史崔德生物公司 | 用於治療雷特症候群之腺相關病毒載體 |
| CN114507692B (zh) * | 2020-11-16 | 2024-07-12 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗法布里病的腺相关病毒载体及其用途 |
| WO2022100748A1 (en) * | 2020-11-16 | 2022-05-19 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof |
| EP4326290A4 (en) * | 2021-04-20 | 2025-05-14 | Walking Fish Therapeutics, Inc. | PRODUCTION OF B-CELL-BASED PROTEIN FACTORIES FOR THE TREATMENT OF SERIOUS DISEASES |
| GB202205514D0 (en) | 2022-04-13 | 2022-05-25 | Freeline Therapeutics Ltd | Mechanical lysis |
| CN114672501B (zh) * | 2022-05-27 | 2022-08-23 | 珠海丽凡达生物技术有限公司 | 一种mRNA、药物组合物及其应用 |
| WO2024044697A2 (en) * | 2022-08-24 | 2024-02-29 | Walking Fish Therapeutics, Inc. | Compositions and methods for treatment of fabry disease |
| WO2024217422A1 (en) * | 2023-04-17 | 2024-10-24 | Exegenesis Bio Co. | Compositions and methods for gene therapies |
| CN116622750B (zh) * | 2023-06-01 | 2024-05-31 | 上海勉亦生物科技有限公司 | 优化的人法布里转基因表达盒及其用途 |
| CN116656704B (zh) * | 2023-06-01 | 2024-11-05 | 华东理工大学 | 用于治疗法布里病的转基因表达盒 |
| WO2025087695A1 (en) | 2023-10-23 | 2025-05-01 | Ascend Advanced Therapies Ltd | Method for producing recombinant adeno-associated virus particles |
Family Cites Families (189)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846968B1 (en) | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| EP0832266A4 (en) | 1995-06-07 | 2000-06-28 | Univ Yale | ORAL ADMINISTRATION OF VECTORS DERIVED FROM THE ADENO ASSOCIATED VIRUS |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| CA2265464C (en) * | 1996-09-13 | 2007-06-26 | Transkaryotic Therapies, Inc. | Therapy for .alpha.-galactosidase a deficiency |
| AU762400B2 (en) | 1996-09-13 | 2003-06-26 | Shire Human Genetic Therapies, Inc. | Therapy for alpha-galactosidase a deficiency |
| US20020082224A1 (en) | 1997-01-14 | 2002-06-27 | Douglas J. Jolly | Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| GB9708526D0 (en) | 1997-04-25 | 1997-06-18 | Royal Free Hosp School Med | Eukaryotic gene expression cassette and uses thereof |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| EP1658857A1 (en) | 1997-10-29 | 2006-05-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US6607879B1 (en) | 1998-02-09 | 2003-08-19 | Incyte Corporation | Compositions for the detection of blood cell and immunological response gene expression |
| WO1999041399A1 (en) | 1998-02-17 | 1999-08-19 | Genzyme Corporation | Methods for purified aav vector production |
| WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| US20090017533A1 (en) | 1998-09-29 | 2009-01-15 | Shire Human Genetic Therapies, Inc., A Delaware Corporation | Optimized messenger rna |
| AU2004242550B2 (en) | 1999-03-11 | 2008-04-03 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-Galactosidase A deficiency |
| GB9909066D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
| EP2275559A3 (en) | 1999-09-28 | 2011-03-23 | Shire Human Genetic Therapies, Inc. | Optimized messenger RNA |
| DE60038045T2 (de) | 1999-11-05 | 2009-02-05 | Jena Bioscience Gmbh | Nicht-pathogenes kinetoplastid protein-expressionssystem |
| WO2001036620A2 (en) | 1999-11-16 | 2001-05-25 | Genzyme Corporation | Vectors and transgenies with regulatory elements for gene delivery to the liver |
| WO2001049830A2 (en) | 1999-12-30 | 2001-07-12 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| WO2001060377A2 (en) | 2000-02-17 | 2001-08-23 | Genzyme Corporation | Methods for treatment of lysosomal storage diseases using biphosphonates |
| JP2003533437A (ja) | 2000-02-17 | 2003-11-11 | ジェンザイム・コーポレイション | 遺伝子デリバリーのための門戸としての肺の遺伝的修飾 |
| US20020081654A1 (en) | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| US6667174B2 (en) | 2000-09-18 | 2003-12-23 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
| EP1624067A3 (en) | 2000-09-18 | 2006-03-15 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
| CA2854685A1 (en) | 2000-10-11 | 2002-08-22 | Richard F Selden | Optimized messenger rna |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| JP2004535801A (ja) | 2001-05-24 | 2004-12-02 | ジェンザイム コーポレイション | 筋特異的発現ベクター |
| JP4742191B2 (ja) | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
| US7063962B2 (en) | 2001-07-20 | 2006-06-20 | Novozymes A/S | DNA sequences for regulating transcription |
| US6749851B2 (en) | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
| US6783968B2 (en) | 2001-09-24 | 2004-08-31 | Clearant, Inc. | Methods for sterilizing preparations of glycosidases |
| US20030064000A1 (en) | 2001-09-24 | 2003-04-03 | Wilson Burgess | Methods of sterilizing biological mixtures using stabilizer mixtures |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| EP1336411A1 (en) | 2002-02-14 | 2003-08-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| BR122017016940B8 (pt) | 2002-04-25 | 2021-07-27 | Transkaryotic Therapies Inc | método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| EP1521523A4 (en) | 2002-05-20 | 2006-04-19 | Univ Texas | METHODS AND COMPOSITIONS FOR DELIVERING NUCLEIC ACID ENZYMES AND MOLECULES IN BRAIN, BONE, AND OTHER FABRICS |
| US20030224477A1 (en) | 2002-05-31 | 2003-12-04 | Heartlein Michael W. | Optimized promoter constructs |
| WO2003101202A1 (en) | 2002-05-31 | 2003-12-11 | Osiris Therapeutics, Inc. | Intraperitoneal delivery of genetically engineered mesenchymal stem cells |
| EP1578367A4 (en) | 2002-11-01 | 2012-05-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
| ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| CN1756558B (zh) | 2003-01-31 | 2012-04-25 | 纽约大学西奈山医学院 | 酶和酶的活性部位特异性陪伴分子的组合 |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| CN1791679A (zh) | 2003-03-19 | 2006-06-21 | 伊索格尼斯股份有限公司 | 基于CD8α链的具有降低的免疫原性的基因治疗载体 |
| US20100196345A1 (en) | 2003-04-27 | 2010-08-05 | Protalix | Production of high mannose proteins in plant culture |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| EP1620133B1 (en) | 2003-05-01 | 2015-12-09 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
| JP2006525371A (ja) | 2003-05-05 | 2006-11-09 | ジェンザイム コーポレイション | 免疫応答を減少させる方法 |
| CN101942442B (zh) | 2003-06-24 | 2013-10-09 | 建新公司 | 新的β-肌动蛋白和RPS21启动子及其应用 |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1694345A1 (en) | 2003-12-04 | 2006-08-30 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
| US20060029656A1 (en) | 2004-02-03 | 2006-02-09 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
| US20080014188A1 (en) | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| US20050208090A1 (en) | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| NZ555830A (en) | 2004-12-15 | 2009-01-31 | Univ North Carolina | Chimeric vectors |
| PL2420256T3 (pl) | 2005-05-02 | 2016-12-30 | Terapia genowa dla zaburzeń neurometabolicznych | |
| US8500720B2 (en) | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
| CA2615218A1 (en) | 2005-07-18 | 2007-01-25 | Protalix Ltd. | Mucosal or enteral administration of biologically active macromolecules |
| EP1945269A4 (en) | 2005-10-31 | 2010-02-17 | Zymequest Inc | NEW A-GALACTOSIDASES |
| TWI500765B (zh) | 2005-11-18 | 2015-09-21 | Tokyo Metropolitan Inst Medical Science | 轉換基質特異性之新穎高機能酵素 |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| US7867484B2 (en) | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| SI1986661T1 (sl) | 2006-02-08 | 2018-12-31 | Genzyme Corporation | Genska terapija za Niemann-Pickovo bolezen tipa A |
| HUE040490T2 (hu) | 2006-02-09 | 2019-03-28 | Genzyme Corp | Lassú intraventrikuláris szállítás |
| AU2007253900A1 (en) | 2006-05-16 | 2007-11-29 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| US20100144008A1 (en) | 2006-12-21 | 2010-06-10 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
| HRP20130744T1 (hr) | 2007-01-18 | 2013-10-11 | Genzyme Corporation | Oligosaharidi koji sadrže aminooksi-skupinu i njezine konjugate |
| CA2584494A1 (en) | 2007-03-27 | 2008-09-27 | Jeffrey A. Medin | Vector encoding therapeutic polypeptide and safety elements to clear transduced cells |
| JP2010523578A (ja) | 2007-03-30 | 2010-07-15 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いるファブリー病の治療方法 |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| EP3252161B1 (en) | 2007-06-06 | 2021-11-17 | Genzyme Corporation | Gene therapy for lysosomal storage diseases |
| WO2009032171A1 (en) | 2007-08-29 | 2009-03-12 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of alpha-galatosidase a |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2252288A1 (en) | 2007-11-21 | 2010-11-24 | Summit Corporation Plc | Treatment of protein folding disorders |
| EP2242840B1 (en) | 2008-01-29 | 2019-07-24 | Applied Genetic Technologies Corporation | Recombinant adeno-associated virus production using bhk cells in suspension |
| LT3470077T (lt) | 2008-02-12 | 2021-02-25 | Amicus Therapeutics, Inc. | Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas |
| WO2009114942A1 (en) * | 2008-03-20 | 2009-09-24 | University Health Network | Thymidylate kinase fusions and uses thereof |
| WO2009137006A2 (en) | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| ES2385735T3 (es) | 2008-06-26 | 2012-07-31 | Orphazyme Aps | Uso de Hsp70 como regulador de la actividad enzimática |
| US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| EP2465542B1 (en) | 2008-12-16 | 2015-01-21 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| ES2634118T3 (es) | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| WO2011019980A1 (en) | 2009-08-14 | 2011-02-17 | University Of Miami | Novel role of alpha-galactosidase activity as a biomarker in kidney disease |
| WO2011039634A2 (en) | 2009-09-29 | 2011-04-07 | Universiteit Gent | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
| JP2013506697A (ja) | 2009-10-06 | 2013-02-28 | アンジオケム インコーポレーテッド | 治療薬を輸送するための組成物と方法 |
| DK2493487T3 (en) | 2009-10-27 | 2016-12-05 | Erytech Pharma | Composition for induction of specific immunological tolerance |
| WO2011057243A2 (en) | 2009-11-09 | 2011-05-12 | University Of Central Florida Research Foundation, Inc. | Administration of plant expressed oral tolerance agents |
| WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| MY160542A (en) | 2009-11-27 | 2017-03-15 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| WO2011088081A1 (en) | 2010-01-12 | 2011-07-21 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| PL2865751T3 (pl) | 2010-03-02 | 2017-03-31 | Protalix Ltd | Stabilizowana alfa-galaktozydaza i jej zastosowania |
| JP2013527753A (ja) | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
| WO2011139379A2 (en) | 2010-05-06 | 2011-11-10 | Duke University | A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities |
| IL291554B2 (en) | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Administering therapeutic agents to the central nervous system |
| WO2012022777A1 (en) | 2010-08-19 | 2012-02-23 | Novozymes A/S | Induced sporulation screening method |
| KR101983572B1 (ko) | 2010-09-29 | 2019-05-29 | 옥시레인 유케이 리미티드 | 만노스-1-포스포-6-만노스 결합의 캡핑제거 및 인산화 n-글리칸의 탈만노실이 가능한 만노시다제 및 당단백질의 활용을 통한 포유류 세포의 촉진방법 |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| WO2012098537A1 (en) | 2011-01-20 | 2012-07-26 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| WO2012125402A2 (en) * | 2011-03-11 | 2012-09-20 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
| ES2745470T3 (es) | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
| US20120283290A1 (en) | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| CN103906527B (zh) | 2011-06-08 | 2020-07-10 | 川斯勒佰尔公司 | Mrna递送的脂质纳米颗粒组合物和方法 |
| US20150258081A1 (en) | 2011-12-22 | 2015-09-17 | Centogene Ip Gmbh | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| CN104428009A (zh) | 2012-02-07 | 2015-03-18 | 全球生物疗法美国有限公司 | 核酸输送的区室化方法及其组合物和应用 |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| BR112014024131A2 (pt) | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
| CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9957495B2 (en) | 2012-04-18 | 2018-05-01 | Vib Vzw | Means and methods for generating improved proteins |
| CA2874316A1 (en) | 2012-05-03 | 2013-11-07 | Indiana University Research And Technology Corporation | Hydrodynamic methods for delivering fluids to kidney tissues and related materials and methods |
| EP2854834A4 (en) | 2012-05-30 | 2016-05-18 | Biostrategies LC | PLANT LENSES AS CARRIER CORRESPONDING AGENTS IN ANIMAL AND HUMAN CELLS |
| US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
| ES2697912T3 (es) | 2012-07-11 | 2019-01-29 | Sangamo Therapeutics Inc | Métodos y composiciones para el tratamiento de enfermedades monogénicas |
| WO2014014938A1 (en) | 2012-07-17 | 2014-01-23 | Amicus Therapeutics, Inc. | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation |
| GB201213117D0 (en) | 2012-07-24 | 2012-09-05 | Ucl Business Plc | Transgene expression |
| WO2014017915A2 (en) | 2012-07-27 | 2014-01-30 | Universiteit Utrecht Holding B.V. | Urea and guanidinium derivatives of iminosugars |
| AU2013296557B2 (en) | 2012-07-31 | 2019-04-18 | Bioasis Technologies Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| US10138474B2 (en) | 2012-08-17 | 2018-11-27 | Research Foundation Of The City University Of New York | Scavenger receptor uptake for fabry disease enzyme replacement therapy |
| ES2968649T3 (es) | 2012-12-07 | 2024-05-13 | Translate Bio Inc | Nanopartículas lipídicas para la administración de ARNm en los pulmones |
| WO2014120900A1 (en) | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
| AU2014244167A1 (en) | 2013-03-13 | 2015-10-08 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| JP6567494B2 (ja) | 2013-03-14 | 2019-08-28 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ４’−チオ−修飾ヌクレオチドを有するリボ核酸及び関連方法 |
| MX2015012873A (es) | 2013-03-15 | 2016-02-03 | Amicus Therapeutics Inc | Reticuladores quimicos. |
| US9447433B2 (en) | 2013-03-15 | 2016-09-20 | The University Of North Carolina At Chapel Hill | Synthetic adeno-associated virus inverted terminal repeats |
| US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| CN115120746A (zh) | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| US20160122727A1 (en) | 2013-06-13 | 2016-05-05 | Shire Human Genetic Therapies, Inc. | Messenger rna based viral production |
| US20140377246A1 (en) | 2013-06-19 | 2014-12-25 | Carol Ann Foundation and International Morquio Organization | Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme |
| RU2664471C2 (ru) | 2013-07-26 | 2018-08-17 | Юниверсити Оф Айова Рисерч Фаундейшн | Способы и композиции для лечения болезней мозга |
| HUE047329T2 (hu) | 2013-08-13 | 2020-04-28 | Univ Northwestern | Peptiddel konjugált részecskék |
| TWI793159B (zh) | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
| WO2015060722A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| ES2821882T3 (es) | 2013-11-15 | 2021-04-28 | Univ Pennsylvania | Composiciones para la supresión de la formación de inhibidores contra el factor VIII en pacientes con hemofilia A. |
| PL3079695T3 (pl) | 2013-12-11 | 2021-09-27 | Genzyme Corporation | Inhibitory syntazy glukozyloceramidu |
| PT3086784T (pt) | 2013-12-23 | 2019-06-27 | Bcn Peptides Sa | Análogos de bicalutamida ou (s)-bicalutamida como compostos ativadores de exocitose para utilização no tratamento de um distúrbio de armazenamento lisossómico ou glicogenose |
| CA2938577A1 (en) | 2014-02-04 | 2015-08-13 | New York University | Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases |
| PT3137497T (pt) | 2014-05-02 | 2021-07-12 | Genzyme Corp | Vetores de aav para terapia genética na retina e snc |
| JP6652334B2 (ja) | 2014-05-31 | 2020-02-19 | Ｊｃｒファーマ株式会社 | ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地 |
| CN106714826A (zh) | 2014-09-07 | 2017-05-24 | 西莱克塔生物科技公司 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
| WO2016077356A2 (en) | 2014-11-10 | 2016-05-19 | Synageva Biopharma Corp. | Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof |
| TW201632626A (zh) | 2014-11-21 | 2016-09-16 | 臺北榮民總醫院 | 製備誘導性多功能幹細胞之方法 |
| EP4023755B1 (en) | 2014-12-12 | 2023-04-26 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
| US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
| LT3237621T (lt) | 2014-12-22 | 2023-09-25 | Codexis, Inc. | Žmogaus alfa-galaktozidazės variantai |
| AU2015373404B2 (en) | 2014-12-30 | 2021-09-09 | CureVac SE | Artificial nucleic acid molecules |
| EP3245220B1 (en) | 2015-01-14 | 2023-09-20 | The University of North Carolina at Chapel Hill | Methods and compositions for targeted gene transfer |
| EP3247808B1 (en) | 2015-01-21 | 2021-05-05 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| LT3256594T (lt) | 2015-02-10 | 2022-02-10 | Genzyme Corporation | Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę |
| WO2016134338A1 (en) | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Recombinant aav vectors for gene therapy of human hematopoietic disorders |
| KR20170116159A (ko) | 2015-02-19 | 2017-10-18 | 다니스코 유에스 인크. | 향상된 단백질 발현 |
| DK3271453T3 (da) | 2015-03-17 | 2021-11-15 | eleva GmbH | Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser |
| CA2979065A1 (en) | 2015-03-24 | 2016-09-29 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| WO2016154313A1 (en) | 2015-03-24 | 2016-09-29 | Zywie, Llc | High drug loading liquid oral pharmaceutical compositions |
| US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
| EP4491733A3 (en) | 2015-04-23 | 2025-03-26 | University of Massachusetts | Modulation of aav vector transgene expression |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| MX2017014443A (es) | 2015-05-15 | 2018-08-01 | Univ Minnesota | Adeno-asociado para administracion terapeutica al sistema nervioso central. |
| EP3303377B1 (en) | 2015-06-05 | 2022-11-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for transient gene therapy with enhanced stability |
| EP3317416A4 (en) | 2015-07-01 | 2018-12-26 | The Regents of The University of California | Retroviral vectors containing a reverse orientation human ubiquitin c promoter |
| WO2017024137A1 (en) | 2015-08-04 | 2017-02-09 | New York University | Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
| US20170051267A1 (en) | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| WO2017049161A1 (en) | 2015-09-18 | 2017-03-23 | Duke University | ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER |
| PT4074331T (pt) | 2015-12-08 | 2025-11-04 | Regeneron Pharmaceuticals Inc | Composições e métodos para a internalização de enzimas |
| CA3008013A1 (en) | 2015-12-14 | 2017-06-22 | The University Of North Carolina At Chapel Hill | Modified capsid proteins for enhanced delivery of parvovirus vectors |
| GB201522243D0 (en) | 2015-12-16 | 2016-01-27 | Ucl Business Plc | Treatment |
| JP6993339B2 (ja) | 2015-12-23 | 2022-02-21 | ダニスコ・ユーエス・インク | タンパク質産生の強化およびその方法 |
| JP6904959B2 (ja) | 2016-01-04 | 2021-07-21 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 結合エピトープを含有する融合タンパク質を封入する粒子 |
| EP3402531A4 (en) | 2016-01-11 | 2019-08-14 | Medgenics Medical Israel Ltd | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| WO2017136202A1 (en) | 2016-02-05 | 2017-08-10 | Emory University | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
-
2015
- 2015-05-11 GB GBGB1508025.2A patent/GB201508025D0/en not_active Ceased
-
2016
- 2016-05-10 DK DK16721916.1T patent/DK3244931T3/en active
- 2016-05-10 PT PT16721916T patent/PT3244931T/pt unknown
- 2016-05-10 CN CN201680027116.1A patent/CN107980063B/zh not_active Expired - Fee Related
- 2016-05-10 KR KR1020177035510A patent/KR20180012772A/ko not_active Ceased
- 2016-05-10 LT LTEP16721916.1T patent/LT3244931T/lt unknown
- 2016-05-10 AU AU2016261453A patent/AU2016261453C1/en not_active Ceased
- 2016-05-10 PL PL16721916T patent/PL3244931T3/pl unknown
- 2016-05-10 CA CA2985935A patent/CA2985935C/en active Active
- 2016-05-10 EP EP18196625.0A patent/EP3470088A1/en active Pending
- 2016-05-10 US US15/573,203 patent/US11103596B2/en active Active
- 2016-05-10 JP JP2017558727A patent/JP6688812B2/ja active Active
- 2016-05-10 HR HRP20190165TT patent/HRP20190165T1/hr unknown
- 2016-05-10 EP EP16721916.1A patent/EP3244931B1/en active Active
- 2016-05-10 TR TR2018/20102T patent/TR201820102T4/tr unknown
- 2016-05-10 ES ES16721916T patent/ES2703814T3/es active Active
- 2016-05-10 WO PCT/GB2016/051328 patent/WO2016181122A1/en not_active Ceased
- 2016-05-11 TW TW105114579A patent/TW201706412A/zh unknown
-
2021
- 2021-07-27 US US17/386,063 patent/US12370268B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2985935A1 (en) | 2016-11-17 |
| US12370268B2 (en) | 2025-07-29 |
| US11103596B2 (en) | 2021-08-31 |
| DK3244931T3 (en) | 2019-02-11 |
| EP3244931A1 (en) | 2017-11-22 |
| US20220016263A1 (en) | 2022-01-20 |
| KR20180012772A (ko) | 2018-02-06 |
| AU2016261453B2 (en) | 2019-03-28 |
| CA2985935C (en) | 2022-03-22 |
| LT3244931T (lt) | 2019-02-11 |
| TR201820102T4 (tr) | 2019-01-21 |
| CN107980063A (zh) | 2018-05-01 |
| PL3244931T3 (pl) | 2019-04-30 |
| US20180110878A1 (en) | 2018-04-26 |
| EP3470088A1 (en) | 2019-04-17 |
| TW201706412A (zh) | 2017-02-16 |
| WO2016181122A1 (en) | 2016-11-17 |
| JP6688812B2 (ja) | 2020-04-28 |
| PT3244931T (pt) | 2019-01-21 |
| GB201508025D0 (en) | 2015-06-24 |
| JP2018520646A (ja) | 2018-08-02 |
| AU2016261453C1 (en) | 2019-09-12 |
| EP3244931B1 (en) | 2018-10-24 |
| CN107980063B (zh) | 2021-12-10 |
| HRP20190165T1 (hr) | 2019-04-05 |
| AU2016261453A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2703814T3 (es) | Terapia génica para la enfermedad de Fabry | |
| US20250236887A1 (en) | Adeno-associated virus (aav) systems for treatment of genetic hearing loss | |
| CN110520536B (zh) | 用于穿过维管结构的基因转移的方法和组合物 | |
| ES2989774T3 (es) | Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos | |
| US10413598B2 (en) | Factor IX gene therapy | |
| US11142775B2 (en) | Bocaparvovirus small noncoding RNA and uses thereof | |
| CN110997923A (zh) | 腺相关病毒载体递送肌肉特异性微肌营养不良蛋白以治疗肌营养不良症 | |
| JP2019506445A (ja) | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 | |
| KR20160026841A (ko) | 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법 | |
| ES2862164T3 (es) | Genoterapia de la enfermedad de Wilson | |
| CN117897492A (zh) | 用于肌肉和cns中的基因表达的杂合启动子 | |
| US20230151390A1 (en) | Vectors for the treatment of acid ceramidase deficiency | |
| JP2024515902A (ja) | 組織向性が改善されたアデノ随伴ウイルスベクターカプシド |